InflaRx
IFRX
InflaRx (IFRX) news
Recent news
Inflarx NV - May offer up to $250 mln in securities - SEC filing
AInvest Wire · Aug 6, 2026Inflarx NV - to engage with EMA on Vilocibimab and Izicopan for AAV approval
InflaRx N.V. (Nasdaq: IFRX) is advancing its development programs for both vilobelimab and izicopan, with a focus on engaging regulatory authorities to support potential approvals in key indications. The company has outlined plans to interact with the European Medicines Agency (EMA) regarding…
AInvest Wire · Jun 30, 2026Inflarx assessing feasibility of strategy for AAV in Europe
AInvest Wire · Jun 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.